Dissemination of transferable AmpC-type beta-lactamase (CMY-10) in a Korean hospital

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
J H LeeSang Hee Lee

Abstract

To determine dissemination and genotype of AmpC beta-lactamases and an extended-spectrum beta-lactamase among clinical isolates of Enterobacteriaceae, we performed antibiotic susceptibility testing, pI determination, induction test, plasmid profiles, transconjugation test, enterobacterial repetitive consensus (ERIC)-PCR, and DNA sequencing. Among the 51 clinical isolates collected from a university hospital in Korea, six isolates were resistant to cephamycins. All six isolates produced a plasmid-encoded AmpC-type beta-lactamase, CMY-10. Five strains also produced one or more other beta-lactamases: SHV-12, an extended-spectrum beta-lactamase (five isolates); TEM-1, a class A beta-lactamase (two isolates); and a chromosomal AmpC beta-lactamase (one isolate, a strain of Enterobacter aerogenes, which produced all four of the beta-lactamases that were identified). One of six isolates produced only CMY-10. ERIC-PCR analysis revealed that dissemination of CMY-10 and SHV-12 was due to a clonal outbreak of a resistant strain and to the interspecies spread of resistance to cephamycins and broad-spectrum beta-lactams in Korea. CMY-10 beta-lactamase genes that are responsible for the resistance to cephamycins (cefoxitin and cefotetan), amo...Continue Reading

References

Nov 11, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C C Sanders, W E Sanders
Jun 1, 1995·Antimicrobial Agents and Chemotherapy·K BushA A Medeiros
Dec 1, 1995·Microbiology·G D Recchia, R M Hall
Oct 1, 1995·Clinical Microbiology Reviews·D M Livermore
Mar 5, 2002·Letters in Applied Microbiology·S H Lee, S H Jeong
May 11, 2002·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Laura VillaAlessandra Carattoli

❮ Previous
Next ❯

Citations

Apr 6, 2006·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Kyungwon LeeYunsop Chong
Oct 8, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F FreitasL Peixe
May 6, 2015·International Journal of Molecular Sciences·Jeong Ho JeonSang Hee Lee
Aug 18, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J S SongS H Lee
Oct 29, 2005·The Lancet Infectious Diseases·Sang Hee LeeSun-Shin Cha
Jul 31, 2007·Future Microbiology·Patrice Nordmann, Hedi Mammeri
Sep 6, 2012·Acta Crystallographica. Section D, Biological Crystallography·James F RubleRachel A Powers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.